RU2006146555A - Инъецируемые фармацевтические композиции позаконазола со стабилизированными частицами - Google Patents
Инъецируемые фармацевтические композиции позаконазола со стабилизированными частицами Download PDFInfo
- Publication number
- RU2006146555A RU2006146555A RU2006146555/15A RU2006146555A RU2006146555A RU 2006146555 A RU2006146555 A RU 2006146555A RU 2006146555/15 A RU2006146555/15 A RU 2006146555/15A RU 2006146555 A RU2006146555 A RU 2006146555A RU 2006146555 A RU2006146555 A RU 2006146555A
- Authority
- RU
- Russia
- Prior art keywords
- posaconazole
- composition according
- composition
- average
- max
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract 13
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 96
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims abstract 78
- 229960001589 posaconazole Drugs 0.000 claims abstract 78
- 239000007853 buffer solution Substances 0.000 claims abstract 16
- 150000003904 phospholipids Chemical class 0.000 claims abstract 10
- 239000001488 sodium phosphate Substances 0.000 claims abstract 8
- 229910000162 sodium phosphate Inorganic materials 0.000 claims abstract 8
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims abstract 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract 7
- 239000003223 protective agent Substances 0.000 claims abstract 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 5
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 claims abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract 3
- 239000004471 Glycine Substances 0.000 claims abstract 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims abstract 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims abstract 2
- 239000000872 buffer Substances 0.000 claims abstract 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000005855 radiation Effects 0.000 claims abstract 2
- 239000001509 sodium citrate Substances 0.000 claims abstract 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000008280 blood Substances 0.000 claims 16
- 210000004369 blood Anatomy 0.000 claims 16
- 208000015181 infectious disease Diseases 0.000 claims 7
- 238000001802 infusion Methods 0.000 claims 7
- 239000004615 ingredient Substances 0.000 claims 6
- 230000036470 plasma concentration Effects 0.000 claims 5
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 4
- 241000222122 Candida albicans Species 0.000 claims 4
- 206010007134 Candida infections Diseases 0.000 claims 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 4
- 229960003942 amphotericin b Drugs 0.000 claims 4
- 201000003984 candidiasis Diseases 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- 239000008215 water for injection Substances 0.000 claims 3
- 241000233866 Fungi Species 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 229940125683 antiemetic agent Drugs 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- 239000003429 antifungal agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 150000003851 azoles Chemical class 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229940009976 deoxycholate Drugs 0.000 claims 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 229960004413 flucytosine Drugs 0.000 claims 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims 2
- 210000003300 oropharynx Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229960002722 terbinafine Drugs 0.000 claims 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 241000223218 Fusarium Species 0.000 claims 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 206010061418 Zygomycosis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000002650 immunosuppressive therapy Methods 0.000 claims 1
- 238000011368 intensive chemotherapy Methods 0.000 claims 1
- 201000009085 invasive aspergillosis Diseases 0.000 claims 1
- 201000007524 mucormycosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 230000002024 thermoprotective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57512604P | 2004-05-28 | 2004-05-28 | |
| US60/575,126 | 2004-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006146555A true RU2006146555A (ru) | 2008-07-20 |
Family
ID=34971355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006146555/15A RU2006146555A (ru) | 2004-05-28 | 2005-05-27 | Инъецируемые фармацевтические композиции позаконазола со стабилизированными частицами |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1761247A1 (enExample) |
| JP (1) | JP2008501034A (enExample) |
| KR (1) | KR20070027564A (enExample) |
| CN (1) | CN1988887A (enExample) |
| AR (1) | AR049063A1 (enExample) |
| AU (1) | AU2005249502A1 (enExample) |
| CA (1) | CA2567803A1 (enExample) |
| IL (1) | IL179627A0 (enExample) |
| MX (1) | MXPA06013886A (enExample) |
| NO (1) | NO20066005L (enExample) |
| PE (1) | PE20060291A1 (enExample) |
| RU (1) | RU2006146555A (enExample) |
| TW (1) | TWI290051B (enExample) |
| WO (1) | WO2005117831A1 (enExample) |
| ZA (1) | ZA200609890B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060009469A1 (en) * | 2004-05-28 | 2006-01-12 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
| RS56044B1 (sr) * | 2006-05-12 | 2017-09-29 | Christian Noe | Primena kombinovanih preparata koji sadrže antimikotike |
| EP2130540A1 (en) | 2008-06-02 | 2009-12-09 | Sandoz AG | Pharmaceutical compositions containing a crystalline form of posaconazole |
| EP2141159A1 (en) | 2008-07-03 | 2010-01-06 | Sandoz AG | A Crystalline form of posaconazole |
| EP2451805A1 (en) | 2009-07-09 | 2012-05-16 | Sandoz AG | A crystalline form of posaconazole |
| WO2011144656A1 (en) | 2010-05-19 | 2011-11-24 | Sandoz Ag | Preparation of posaconazole intermediates |
| WO2011144655A1 (en) | 2010-05-19 | 2011-11-24 | Sandoz Ag | Process for the preparation of chiral hydrazides |
| CA2798010C (en) | 2010-05-19 | 2018-09-25 | Sandoz Ag | Purification of posaconazole and of posaconazole intermediates |
| RU2585760C2 (ru) | 2010-05-19 | 2016-06-10 | Сандоз Аг | Способ получения хиральных триазолонов |
| EP3391890B1 (en) * | 2010-06-29 | 2021-08-25 | Merck Sharp & Dohme Corp. | Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin |
| CN108329303A (zh) | 2011-06-16 | 2018-07-27 | 桑多斯股份公司 | 制备手性化合物的方法 |
| CN103284959B (zh) * | 2012-02-22 | 2015-06-03 | 重庆圣华曦药业股份有限公司 | 泊沙康唑冻干粉针剂及制备方法 |
| CN102755628B (zh) * | 2012-07-16 | 2013-10-23 | 中国科学院微生物研究所 | 一种抗真菌的药物组合物 |
| CN102805731B (zh) * | 2012-08-22 | 2014-04-30 | 北京莱瑞森医药科技有限公司 | 泊沙康唑干混悬剂及其制备方法 |
| CN105030668B (zh) * | 2015-06-26 | 2018-03-27 | 济川药业集团有限公司 | 泊沙康唑口服混悬剂及其制备方法 |
| CN106333925B (zh) * | 2015-07-10 | 2019-06-18 | 上海美悦生物科技发展有限公司 | 一种泊沙康唑液体混悬剂及其制备方法 |
| CN105997872B (zh) * | 2016-07-08 | 2019-02-19 | 河南省立眼科医院 | 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液 |
| CN110582264B (zh) * | 2017-03-26 | 2022-11-11 | V·R·斯塔福德 | 眼睑皮肤状况的处理方法 |
| CA3063115A1 (en) * | 2017-04-12 | 2018-10-18 | Vikash J. BHAGWANDIN | Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors |
| CN110507609B (zh) * | 2018-05-21 | 2021-09-17 | 上海医药工业研究院 | 泊沙康唑口服混悬剂的制备方法 |
| CN111514146A (zh) * | 2020-04-28 | 2020-08-11 | 山西振东泰盛制药有限公司 | 含有泊沙康唑的药物组合物 |
| CN113933131B (zh) * | 2021-09-24 | 2024-01-26 | 合肥天一生物技术研究所有限责任公司 | 一种阴道微生物荧光染色液 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| EP2090165A3 (en) * | 2001-04-03 | 2012-03-28 | Schering Corporation | Antifungal composition with enhanced bioavailability |
-
2005
- 2005-05-27 PE PE2005000599A patent/PE20060291A1/es not_active Application Discontinuation
- 2005-05-27 CN CNA2005800248542A patent/CN1988887A/zh active Pending
- 2005-05-27 RU RU2006146555/15A patent/RU2006146555A/ru not_active Application Discontinuation
- 2005-05-27 AU AU2005249502A patent/AU2005249502A1/en not_active Abandoned
- 2005-05-27 TW TW094117524A patent/TWI290051B/zh not_active IP Right Cessation
- 2005-05-27 WO PCT/US2005/018945 patent/WO2005117831A1/en not_active Ceased
- 2005-05-27 CA CA002567803A patent/CA2567803A1/en not_active Abandoned
- 2005-05-27 AR ARP050102203A patent/AR049063A1/es not_active Application Discontinuation
- 2005-05-27 EP EP05755118A patent/EP1761247A1/en not_active Withdrawn
- 2005-05-27 MX MXPA06013886A patent/MXPA06013886A/es unknown
- 2005-05-27 KR KR1020067024996A patent/KR20070027564A/ko not_active Withdrawn
- 2005-05-27 JP JP2007515456A patent/JP2008501034A/ja not_active Withdrawn
-
2006
- 2006-11-27 IL IL179627A patent/IL179627A0/en unknown
- 2006-11-27 ZA ZA200609890A patent/ZA200609890B/xx unknown
- 2006-12-22 NO NO20066005A patent/NO20066005L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20066005L (no) | 2007-02-27 |
| EP1761247A1 (en) | 2007-03-14 |
| TWI290051B (en) | 2007-11-21 |
| WO2005117831A1 (en) | 2005-12-15 |
| AR049063A1 (es) | 2006-06-21 |
| ZA200609890B (en) | 2008-09-25 |
| KR20070027564A (ko) | 2007-03-09 |
| PE20060291A1 (es) | 2006-04-14 |
| CN1988887A (zh) | 2007-06-27 |
| JP2008501034A (ja) | 2008-01-17 |
| TW200609001A (en) | 2006-03-16 |
| AU2005249502A1 (en) | 2005-12-15 |
| CA2567803A1 (en) | 2005-12-15 |
| IL179627A0 (en) | 2007-05-15 |
| MXPA06013886A (es) | 2007-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006146555A (ru) | Инъецируемые фармацевтические композиции позаконазола со стабилизированными частицами | |
| US8551942B2 (en) | Lyophilized anti-fungal compositions | |
| US8431539B2 (en) | Formulations of daptomycin | |
| US11819533B2 (en) | Compositions and methods for the treatment of fungal infections | |
| US9393307B2 (en) | Caspofungin composition | |
| US8980827B2 (en) | Medicinal composition containing echinocandin antifungal agent micafungin and preparation method and use thereof | |
| ES2298821T3 (es) | Utilizacion de un agente antifungico de equinocandina en combinacion con un agente antibacteriano glicopeptidico. | |
| NZ516108A (en) | Ophthalmic composition containing ketotifen and a non-ionic tonicity agent | |
| TW200423871A (en) | Topical parasiticide formulations and methods of treatment | |
| CN101351219A (zh) | 包含增效比例的干扰素γ和α的稳定的制剂 | |
| CN101637447B (zh) | 一种西他沙星注射剂及其制备方法 | |
| US11931362B2 (en) | Stable pharmaceutical formulations of pemetrexed | |
| AU2019328599B2 (en) | Compounds and methods for treating fungal infections | |
| CN112569229A (zh) | 包含奥硝唑类化合物的制剂及其制备方法和用途 | |
| US20100210681A1 (en) | Aqueous pharmaceutical composition | |
| JP2007535545A (ja) | 難吸収性薬剤の経口投与のための製剤 | |
| US20210315898A1 (en) | Combination therapy for treating cancer | |
| CN116251168A (zh) | 一种棘白素类似物的药物组合物及其制备方法 | |
| SK8702001A3 (en) | Cyclosporin solution | |
| OA20177A (en) | Compounds and methods for treating fungal infections. | |
| TW202529794A (zh) | 液態西曲瑞克（Ｃｅｔｒｏｒｅｌｉｘ）組合物 | |
| US20240180935A1 (en) | Solution formulation of cyclophosphamide | |
| CN1256631A (zh) | 治疗哺乳动物真菌感染的方法和组合物 | |
| RU2333766C2 (ru) | Способы введения далбаванцина для лечения бактериальных инфекций | |
| JP2025535828A (ja) | エキノカンジン類似体の医薬組成物及びその調製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090929 |